Author: PWeekly

Using 2017 USRDS data, researchers identified dialysis patients aged 18 and older with Medicare as the primary payer. Baseline characteristics and comorbid conditions for patients with gout who were dialysis-dependent were...

Prior research has shown that pegloticase therapy for uncontrolled gout does not require renal adjustments and is effective across all stages of CKD. Pegloticase with immunomodulating (IMM) co-therapy demonstrated an increased...

Since patients with CKD are at increased risk for gout and alkalinization solubilizes uric acid, investigators sought to determine if baseline bicarbonate or change in bicarbonate was an independent predictor of incident gout in...

With evidence that gout highly impacts patients with advanced CKD, through increased healthcare utilization and higher cardiovascular and bone/joint comorbidity and patients with uncontrolled gout (UCG) show to have an even...

In patients with chronic refractory gout whose serum urate (SU) was not maintained at ≤6 mg/dL, adding an additional tolerizing dose of pegloticase between the first and second biweekly administrations showed an overall response...

Serum urate (SU) responders to pegloticase experienced significant reductions in mean arterial pressure (MAP) that were independent of changes in renal function, according to prior randomized clinical trials (RCTs). To determine...

Small clinical trials have shown that concomitant immunomodulatory (IMM) drug use improves pegloticase persistence in the treatment of gout. However, real-world evidence has been lacking. Therefore, researchers evaluated...

In a large cohort of older patients with gout who started urate-lowering therapy (ULT), researchers observed a decrease in the rate in major adverse cardiovascular events (MACE) with a treat-to-target (TTT) strategy compared...